> Stopping an experiment once you find a significant effect but before you reach your predetermined sample size is classic P hacking.
Although much of the article is basic common sense, and although I'm not a statistician, I had to seriously question the author's understanding of statistics at this point. The predetermined sample size (statistical power) is usually based on an assumption made about the effect size; if the effect size turns out to be much larger than you assumed, then a smaller sample size can be statistically sound.
Clinical trials very frequently do exactly this -- stop before they reach a predetermined sample size -- by design, once certain pre-defined thresholds have been passed. Other than not having to spend extra time and effort, the reasons are at least twofold: first, significant early evidence of futility means you no longer have to waste patients' time; second, early evidence of utility means you can move an effective treatment into practice that much sooner.
A classic example of this was with clinical trials evaluating the effect of circumcision on susceptibility to HIV infection; two separate trials were stopped early when interim analyses showed massive benefits of circumcision [0, 1].
In experimental studies, early evidence of efficacy doesn't mean you stop there, report your results, and go home; the typical approach, if the experiment is adequately powered, is to repeat it (three independent replicates is the informal gold standard).
[0]: https://pubmed.ncbi.nlm.nih.gov/17321310/
[1]: https://pubmed.ncbi.nlm.nih.gov/16231970/